scholarly journals Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers

2021 ◽  
Author(s):  
Athénaïs Boucly ◽  
Laurent Savale ◽  
Xavier Jaïs ◽  
Marc Humbert ◽  
Olivier Sitbon ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Sequential Combination

scholarly journals Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium

2021 ◽  
Author(s):  
Hiromitsu Noguchi ◽  
Masahide Kubo ◽  
Kayo Kashiwada‐Nakamura ◽  
Katsunari Makino ◽  
Jun Aoi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Tinea Unguium ◽  
Sequential Combination ◽  
Oral Terbinafine

scholarly journals Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome

2009 ◽  
Vol 3 (1) ◽  
pp. 18-21 ◽  
Author(s):  
C. E. Huber ◽  
A. G. Judex ◽  
J. Freyschmidt ◽  
S. Feuerbach ◽  
J. Scholmerich ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Sapho Syndrome ◽  
Sustained Remission ◽  
Sequential Combination

scholarly journals Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)

2020 ◽  
Vol 10 (3) ◽  
pp. 204589402094212
Author(s):  
Hossein-Ardeschir Ghofrani ◽  
Ekkehard Grünig ◽  
Pavel Jansa ◽  
David Langleben ◽  
Stephan Rosenkranz ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Receptor Antagonist ◽  
Endothelin Receptor Antagonist ◽  
Walking Distance ◽  
Endothelin Receptor ◽  
Pretreated Patients ◽  
Sequential Combination ◽  
Pulmonary Arterial

Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg–maximum ( N = 131 pretreated patients) and placebo ( N = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: –8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.

scholarly journals The role of combination therapy in managing pulmonary arterial hypertension

2014 ◽  
Vol 23 (134) ◽  
pp. 469-475 ◽  
Author(s):  
Hossein-Ardeschir Ghofrani ◽  
Marc Humbert
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Treatment Algorithm ◽  
Supporting Evidence ◽  
Potential Clinical Benefit ◽  
Treatment Naïve ◽  
Sequential Combination ◽  
Pulmonary Arterial ◽  
Randomised Controlled

Pulmonary arterial hypertension (PAH) is a complex, progressive disease with several pathobiological mechanisms, including the endothelin, nitric oxide and prostacyclin pathways. Current treatments for PAH target one of these pathways and, in more severe cases or instances of disease worsening, may be combined with a view to target multiple pathways in parallel. Treatment combination is performed sequentially (as an intensification from initial monotherapy) or upfront (use of two or more therapies in treatment-naïve patients). Whilst combination therapy has been historically considered to be an option for the treatment of PAH, supporting evidence was typically limited to expert opinion, clinical experience and registry data.Data from randomised controlled trials on sequential combination therapy in particular has grown in recent years, resulting in a change in the level of recommendations in the latest update to the PAH treatment algorithm. However, short-term trials have shown inconsistent results, and have not been powered to assess morbidity/mortality outcomes. More recent data from long-term trials suggest a potential clinical benefit associated with sequential combination therapy.In this review we will introduce the concept of combination therapy, consider the latest evidence for both sequential and upfront combination therapy, and discuss additional considerations when initiating combination therapy in clinical practice.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

2010 ◽  
Vol 27 (1) ◽  
pp. 189-195 ◽  
Author(s):  
Bhavik J. Pandya ◽  
Morgan Bron ◽  
Therese McCall ◽  
Andrew P. Yu ◽  
Kristina S. Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Sequential Combination

A poly(ascorbyl acrylate)-containing nanoplatform with anticancer activity and the sequential combination therapy with its loaded paclitaxel

2016 ◽  
Vol 4 (40) ◽  
pp. 6588-6596 ◽  
Author(s):  
Yufeng Song ◽  
Yanqi Xie ◽  
Junjiao Yang ◽  
Ruiqiong Li ◽  
Xu Jin ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Anticancer Activity ◽  
Therapeutic Agents ◽  
Tumor Inhibition ◽  
Sequential Combination

The complex nanocarriers combined with the loaded therapeutic agents to achieve synergistic tumor inhibition.

scholarly journals Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment

2015 ◽  
Vol 59 (7) ◽  
pp. 4121-4128 ◽  
Author(s):  
Guo-Jun Li ◽  
Yi-Qi Yu ◽  
Shao-Long Chen ◽  
Ping Fan ◽  
Ling-Yun Shao ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Combination Therapy ◽  
Therapy Group ◽  
Hepatitis B Surface Antigen ◽  
Hbeag Seroconversion ◽  
Pegylated Interferon ◽  
Hepatitis B E Antigen ◽  
Sequential Combination

ABSTRACTNucleos(t)ide analogues rarely result in a durable off-treatment response in chronic hepatitis B infection, whereas pegylated interferon (Peg-IFN) induces a long-lasting response only in a subset of patients. We assessed the effect of sequential combination therapy with Peg-IFN-α2a and entecavir in hepatitis B e antigen (HBeAg)-positive patients with prior long-term entecavir therapy and investigated the predictors of response to treatment. HBeAg-positive individuals who did not achieve HBeAg seroconversion during previous long-term entecavir therapy, receiving Peg-IFN-α2a added to ongoing entecavir therapy (sequential combination [S-C] therapy;n= 81) for 48 weeks or remaining on entecavir monotherapy (n= 116), were retrospectively included. A matched pair was created at a 1:1 ratio from each treatment group. The primary endpoint was HBeAg seroconversion at week 48. Subgroup analysis of response prediction was conducted for 81 patients with S-C therapy. More patients in the S-C therapy group achieved HBeAg seroconversion than those in the entecavir group (44% versus 6%;P< 0.0001). An HBeAg level of <200 signal-to-cutoff ratio (S/CO) at baseline was a strong predictor for higher HBeAg seroconversion than that achieved when HBeAg was ≥200 S/CO (64.2% versus 17.9%;P< 0.0001). Hepatitis B surface antigen (HBsAg) levels at baseline and the decrease in HBsAg levels predicted HBsAg loss in the S-C therapy group. The combination of baseline HBeAg of <200 S/CO and HBsAg of <1,000 IU/ml and an HBsAg decline at week 12 of ≥0.5 log10IU/ml provided the highest rate of HBeAg seroconversion (92.31%) and HBsAg loss (83.3%) at week 48. Patients receiving sequential combination therapy have a higher rate of HBeAg seroconversion and are more likely to experience HBsAg clearance than do those continuing entecavir monotherapy. Sequential combination therapy can be guided by baseline HBsAg/HBeAg levels and on-treatment HBsAg dynamics.

Smart Porous Silicon Nanoparticles with Polymeric Coatings for Sequential Combination Therapy

2015 ◽  
Vol 12 (11) ◽  
pp. 4038-4047 ◽  
Author(s):  
Wujun Xu ◽  
Rinez Thapa ◽  
Dongfei Liu ◽  
Tuomo Nissinen ◽  
Sari Granroth ◽  
...  
Keyword(s):  
Porous Silicon ◽  
Combination Therapy ◽  
Silicon Nanoparticles ◽  
Polymeric Coatings ◽  
Porous Silicon Nanoparticles ◽  
Sequential Combination
Sign in / Sign up

Export Citation Format

Share Document